Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Share-based Compensation (2022 - 2025)

Taysha Gene Therapies' Share-based Compensation history spans 4 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 2.14% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $13.0 million, up 9.53%, while the annual FY2024 figure was $13.1 million, 65.76% up from the prior year.
  • Share-based Compensation for Q3 2025 was $3.3 million at Taysha Gene Therapies, up from $3.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.3 million in Q1 2022 and bottomed at $1.7 million in Q1 2023.
  • The 4-year median for Share-based Compensation is $3.3 million (2025), against an average of $3.3 million.
  • The largest annual shift saw Share-based Compensation tumbled 68.57% in 2023 before it surged 90.93% in 2024.
  • A 4-year view of Share-based Compensation shows it stood at $4.1 million in 2022, then plummeted by 52.04% to $2.0 million in 2023, then skyrocketed by 63.41% to $3.2 million in 2024, then rose by 2.15% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Share-based Compensation are $3.3 million (Q3 2025), $3.2 million (Q2 2025), and $3.3 million (Q1 2025).